Autologous lymphoma vaccines induce human T cell responses against multiple, unique epitopes

被引:52
作者
Baskar, S
Kobrin, CB
Kwak, LW
机构
[1] Natl Canc Inst, Basic Res Program, SAIC Frederick Inc, Frederick, MD 21702 USA
[2] NIH, Expt Transplantat & Immunol Branch, Ctr Canc Res, Frederick, MD USA
关键词
D O I
10.1172/JCI200420312
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The clonotypic surface Ig receptor expressed by malignant B cells, idiotype, is a tumor-specific antigen and an attractive target for active immunotherapy. While Ab's specific for tumor idiotype have been well described in patients with B cell malignancies, the precise antigenic epitopes in human idiotype recognized by autologous T cells remain largely unknown. We report here that T cell lines generated from lymphoma patients actively immunized with idiotype protein specifically recognized multiple, unique immunodominant epitopes in autologous tumor idiotype. Synthetic peptides corresponding to hypervariable, but not framework, regions of Ig heavy chain specifically stimulated CD4(+) and CD8(+) T cells to proliferate and secrete proinflammatory cytokines in an MHC-associated manner. Detailed analysis revealed a minimal determinant of an immunodominant epitope, comprising critical residues at the amino terminus that may be a product of somatic hypermutation. Association of idiotype-specific T cell responses with previously documented molecular remissions in idiotype-vaccinated patients suggests that the newly identified T cell epitopes may be clinically relevant. Such antigenic epitopes may serve as candidates for novel peptide-vaccine strategies, and as tools to selectively expand tumor antigen-specific T cells for adoptive immunotherapy and for monitoring T cell immunity in vaccinated patients.
引用
收藏
页码:1498 / 1510
页数:13
相关论文
共 50 条
  • [1] BAKKUS MHC, 1992, BLOOD, V80, P2326
  • [2] BASKAR S, 1992, J IMMUNOL, V148, P2378
  • [3] Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma
    Bendandi, M
    Gocke, CD
    Kobrin, CB
    Benko, FA
    Sternas, LA
    Pennington, R
    Watson, TM
    Reynolds, CW
    Gause, BL
    Duffey, PL
    Jaffe, ES
    Creekmore, SP
    Longo, DL
    Kwak, LW
    [J]. NATURE MEDICINE, 1999, 5 (10) : 1171 - 1177
  • [4] BOON T, 1994, ANNU REV IMMUNOL, V12, P337, DOI 10.1146/annurev.iy.12.040194.002005
  • [5] Dutoit V, 2001, CANCER RES, V61, P5850
  • [6] Fagerberg J, 1999, INT J CANCER, V80, P671, DOI 10.1002/(SICI)1097-0215(19990301)80:5<671::AID-IJC7>3.0.CO
  • [7] 2-E
  • [8] MUC-1 EPITHELIAL TUMOR MUCIN-BASED IMMUNITY AND CANCER VACCINES
    FINN, OJ
    JEROME, KR
    HENDERSON, RA
    PECHER, G
    DOMENECH, N
    MAGARIANBLANDER, J
    BARRATTBOYES, SM
    [J]. IMMUNOLOGICAL REVIEWS, 1995, 145 : 61 - 89
  • [9] THE BIOCHEMISTRY AND CELL BIOLOGY OF ANTIGEN PROCESSING AND PRESENTATION
    GERMAIN, RN
    MARGULIES, DH
    [J]. ANNUAL REVIEW OF IMMUNOLOGY, 1993, 11 : 403 - 450
  • [10] Gricks CS, 2001, CANCER RES, V61, P5145